Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells

Chen J.-C.JEN-CHANG KOTaso Y.-C.Cheng H.-H.Chen T.-Y.Yen T.-C.Lin Y.-W.2021-10-042021-10-0420210031-7012https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096700841&doi=10.1159%2f000509052&partnerID=40&md5=d61fe3cc4150c45ab89eb56b211cb2b5https://scholars.lib.ntu.edu.tw/handle/123456789/583863Introduction: Xeroderma pigmentosum complementation group C (XPC) protein is an important DNA damage recognition factor involved in nucleotide excision repair and regulation of non-small-cell lung cancer (NSCLC) cell proliferation and viability. 17-Allyla[SDGs]SDG3bevacizumab; protein kinase B; tanespimycin; xeroderma pigmentosum group C protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; angiogenesis inhibitor; antineoplastic agent; benzoquinone derivative; bevacizumab; chromone derivative; DNA binding protDownregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cellsjournal article10.1159/000509052332024062-s2.0-85096700841